Enterovirus Vaccine for Diabetes Type 1

Enterovirus vaccine for diabetes type 1 -  Type 1 diabetes is increasing worldwide and to this day, the exact cause of the disease is unknown. Enterovirus (the most common viruses that attack humans) is one of the environmental factors that have been touted as a potential cause of disease. However, there is no strong evidence that proves their role. In this study, Stone et al. have taken initial steps to determine the involvement of this virus through testing a new prototype vaccine efficacy in preventing type 1 diabetes after experimental infection of enterovirus. Vaccination in individuals at risk with such vaccines and subsequent monitoring of the onset of the disease may reveal a role for this virus in type 1 diabetes. Furthermore, if the enterovirus vaccine, vaccination with involved enterovirus will give preventative treatment for type 1 diabetes that is caused by viruses.

Type 1 diabetes is the most common disease, chronic, and life-threatening in children. Finland and Sweden have the highest incidence of type 1 diabetes in the world with over 1 200 suffered from the disease in Sweden. This disease is caused by the destruction of the cells in the pancreas that produce insulin, the hormone responsible for regulating blood sugar levels. There are currently no preventive care and disease requires a lifelong insulin injection to survive. Enterovirus vaccine for diabetes type 1 -  Type 1 diabetes is also associated with severe complications and shorten the age including cardiovascular disease, vision loss and the risk of lower extremity amputation, and thereby, placing a heavy burden on the affected individual and health care system in General.

Currently, there is no commercially available vaccine for human use targeting enterovirus associated with type 1 diabetes in humans. For the first time, this research by Stone et al. reported that vaccine described preventing diabetes caused by enterovirus in the clinically relevant model for type 1 diabetes. In addition, it also protected against other signs of infection seen in control animals and have no adverse effect on the animals that are vaccinated.

 "This encouraging result suggests that the vaccine actually protects against diabetes induced by the virus shows the potential of the vaccine to explain the role of enterovirus in human type 1 diabetes, " said Prof. Malin Flodström-Tullberg at Karolinska Institute which is responsible for the group. for the pre-clinical studies.

The researchers are keen to continue this research as defined by Dr. Vesa Hytönen, which produces the vaccine prototype:  "Model described in this paper provides a very good platform to test a vaccine for enterovirus further containing more potential virus diabetogenic. Enterovirus vaccine for diabetes type 1 -  Through this study is proof of concepts we wish to develop and validate the enterovirus vaccine experiment similar to poliovirus vaccine commonly used, which has the potential to determine whether enterovirus role in type 1 diabetes. "

Work is currently underway at the University of Tampere to develop vaccines that target more viruses than a single virus vaccine described in this study, and proposed all viruses have been implicated in type 1 diabetes. This experimental model provides an interesting opportunity to study further the concept of evidence before it progressed to clinical settings in humans.

 "Experiment here is an important step towards the use of new enterovirus vaccine clinical. Such a vaccine is being developed further by Vactech Ltd. and his collaborations, Prevention Bio, for testing in clinical settings  ", said Professor Heikki Hyöty, University of Tampere, the author in this study and one of the pioneers in the This area of research.

This article has been published of the material provided by the University of Tampere. Note: the material may have been altered for length and substance. Enterovirus vaccine for diabetes type 1 -  For more information, please contact the source cited.

Share this post